Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Isotope & RadiationHKSE:01763 +0.95%92 Interest Coverage is 16.93 as of Dec. 2025, which is 30% below its 10-year median of 24.09. GuruFocus rates HKSE:01763 with a GF Score™ of 92/100 and a GF Value™ of HK$15.74 (Fairly Valued). The stock has 5 warning signs investors should review. Among 467 Medical Devices & Instruments companies, China Isotope & Radiation ranks worse than 51.82% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. China Isotope & Radiation's
Operating Income
for the
six
months ended in Dec. 2025 was HK$661 Mil. China Isotope & Radiation's Interest Expense for the
six
months ended in Dec. 2025 was HK$-39 Mil.
China Isotope & Radiation's interest coverage for the quarter that ended in Dec. 2025 was 16.93.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for China Isotope & Radiation's Interest Coverage or its related term are showing as below:
HKSE:01763'
s Interest Coverage Range Over the Past 10 Years
Min: 16.09 Med: 24.09 Max: 77
Current: 16.09
HKSE:01763's Interest Coverage is ranked worse than 51.82% of 467
companies
in the Medical Devices & Instruments industry
Industry Median: 17.07
vs HKSE:01763: 16.09
China Isotope & Radiation (HKSE:01763) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
China Isotope & Radiation Interest Coverage Related Terms
China Isotope & Radiation Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
HKSE:01763 vs ABT, SYK, MDT: Interest Coverage Comparison
For the Medical Devices subindustry, China Isotope & Radiation's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Isotope & Radiation Interest Coverage vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, China Isotope & Radiation's Interest Coverage distribution charts can be found below:
* The bar in red indicates where China Isotope & Radiation's Interest Coverage falls into.
China Isotope & Radiation Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Isotope & Radiation (HKSE:01763) has a Interest Coverage of 16.93 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on China Isotope & Radiation and its competitors. This is 30% below median its historical median of 24.09. Over the past decade, China Isotope & Radiation's Interest Coverage has ranged from 16.09 to 77.00. According to the industry distribution chart, China Isotope & Radiation ranks #242 out of 467 companies in the Medical Devices & Instruments industry, placing it in the top 51.8%.
Is China Isotope & Radiation's Interest Coverage too high?
China Isotope & Radiation's current Interest Coverage of 16.93 is 30% below median its 10-year median of 24.09. Over the past 10 years, this metric has ranged from a low of 16.09 to a high of 77.00. The Medical Devices & Instruments industry median Interest Coverage is 17.07. China Isotope & Radiation's value of 16.93 is 0.8% below this industry median. Based on the distribution chart, China Isotope & Radiation ranks #242 out of 467 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, China Isotope & Radiation has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does China Isotope & Radiation's Interest Coverage compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, China Isotope & Radiation ranks #242 out of 467 companies for Interest Coverage. This places China Isotope & Radiation in the lower half of its industry. The industry median Interest Coverage is 17.07. China Isotope & Radiation's value of 16.93 is 0.8% below this benchmark. Historically, China Isotope & Radiation's own Interest Coverage has ranged from 16.09 to 77.00 over the past decade. While the company's 10-year median is 24.09 vs. the industry median of 17.07, China Isotope & Radiation has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Devices & Instruments company?
The median Interest Coverage among Medical Devices & Instruments companies is 17.07, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Isotope & Radiation's current Interest Coverage of 16.93 is 0.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on China Isotope & Radiation and its competitors. For the Medical Devices & Instruments industry, the median Interest Coverage is 17.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Isotope & Radiation's current Interest Coverage is 16.93, which is 30% below median its own 10-year median of 24.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Isotope & Radiation stock overvalued right now?
Based on GuruFocus' analysis, China Isotope & Radiation (HKSE:01763) is currently considered Fairly Valued. The stock's GF Value™ is HK$15.74, compared to a current price of HK$17.02 — trading 8.1% above its estimated fair value. The current Interest Coverage is 16.93, which is 30% below median its 10-year median of 24.09 and 0.8% below the Medical Devices & Instruments industry median of 17.07. China Isotope & Radiation's overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For China Isotope & Radiation (HKSE:01763), the current Interest Coverage is 16.93 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Isotope & Radiation (HKSE:01763) Overvalued in 2026?
Based on GuruFocus' analysis, China Isotope & Radiation stock appears to be overvalued.
The current stock price of HK$17.02 is trading 8.1% above its estimated GF Value™ of HK$15.74.
GuruFocus considers China Isotope & Radiation to be Fairly Valued.
Key valuation signals for HKSE:01763:
Interest Coverage: 16.93 (30% below median its 10-year median of 24.09)
GF Value™: HK$15.74 vs. price of HK$17.02 (8.1% above fair value)
Industry Position: 0.8% below the Medical Devices & Instruments median (#242 of 467)
No single metric tells the full story. See the HKSE:01763 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Isotope & Radiation Corp is a Chinese company. It has five operating segments: (1) nuclear medicine; (2) radioactive source products; (3) irradiation; (4) nuclear medical equipment and related services; and (5) other businesses. Nuclear medicines: manufacturing and sale of a range of imaging diagnostic and therapeutic radio pharmaceuticals imaging, UBT diagnostic kits and test analysers and other products. Its radioactive source products segment involves the sale of medical and industrial radioactive source products and technical services. The company's operations are carried out and a majority of its customers are located in the PRC.
92GF Score
Get the complete analysis for HKSE:01763
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01763 has been successfully added to your 
